Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 374

1.

α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.

Huang JR, Tsai YC, Chang YJ, Wu JC, Hung JT, Lin KH, Wong CH, Yu AL.

J Immunol. 2014 Feb 15;192(4):1972-81. doi: 10.4049/jimmunol.1302623. Epub 2014 Jan 24.

2.

PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.

Wang XF, Lei Y, Chen M, Chen CB, Ren H, Shi TD.

J Viral Hepat. 2013 Apr;20 Suppl 1:27-39. doi: 10.1111/jvh.12061.

PMID:
23458522
3.

Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Wu J, Shin J, Xie D, Wang H, Gao J, Zhong XP.

J Immunol. 2014 Mar 15;192(6):2643-50. doi: 10.4049/jimmunol.1302076. Epub 2014 Feb 14.

4.

Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.

Nishihori Y, Kato K, Tanaka M, Okamoto T, Hagiwara S, Araki N, Kogawa K, Kuribayashi K, Nakamura K, Niitsu Y.

Cancer Biol Ther. 2009 Sep;8(18):1763-70.

PMID:
19901518
5.

Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1.

Kojo S, Elly C, Harada Y, Langdon WY, Kronenberg M, Liu YC.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17847-51. doi: 10.1073/pnas.0904078106. Epub 2009 Oct 7.

6.
7.

A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by alpha-galactosylceramide.

Cao Z, Dhupar R, Cai C, Li P, Billiar TR, Geller DA.

J Immunol. 2010 Aug 15;185(4):2536-43. doi: 10.4049/jimmunol.1000092. Epub 2010 Jul 12.

8.

Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.

Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S.

J Immunol. 2001 Jun 1;166(11):6578-84.

9.

Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.

Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, Wong CH, Yu AL.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10299-304. Epub 2007 Jun 12.

10.

Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.

Inui T, Nakagawa R, Ohkura S, Habu Y, Koike Y, Motoki K, Kuranaga N, Fukasawa M, Shinomiya N, Seki S.

J Immunol. 2002 Dec 1;169(11):6127-32.

11.

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.

Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T.

J Exp Med. 1999 Apr 5;189(7):1121-8.

12.

Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor.

Cao Z, Yuan Y, Jeyabalan G, Du Q, Tsung A, Geller DA, Billiar TR.

Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G249-58. doi: 10.1152/ajpgi.00041.2009. Epub 2009 Jun 25.

13.

Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells.

Parekh VV, Wu L, Olivares-Villagómez D, Wilson KT, Van Kaer L.

J Immunol. 2013 Mar 1;190(5):1948-60. doi: 10.4049/jimmunol.1201718. Epub 2013 Jan 23.

14.

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.

Parekh VV, Singh AK, Wilson MT, Olivares-Villagómez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang CR, Joyce S, Van Kaer L.

J Immunol. 2004 Sep 15;173(6):3693-706.

15.

Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.

Gebremeskel S, Clattenburg DR, Slauenwhite D, Lobert L, Johnston B.

Oncoimmunology. 2015 Jan 22;4(3):e995562. eCollection 2015 Mar.

16.

β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.

O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzofsky JA.

Clin Cancer Res. 2013 Aug 15;19(16):4404-11. doi: 10.1158/1078-0432.CCR-12-2169. Epub 2013 Jun 26.

17.

Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.

Habu Y, Uchida T, Inui T, Nakashima H, Fukasawa M, Seki S.

Immunology. 2004 Sep;113(1):35-43.

18.

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV.

J Immunol. 2009 Mar 1;182(5):2816-26. doi: 10.4049/jimmunol.0803648.

19.
20.

Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, Delovitch TL.

Clin Exp Immunol. 2011 Apr;164(1):26-41. doi: 10.1111/j.1365-2249.2011.04323.x. Epub 2011 Mar 1.

Items per page

Supplemental Content

Write to the Help Desk